All In Biotech

Drug Trial Radar · NCT06597344

A Study in Adolescent and Adult Female Participants to Evaluate Clinical Symptom Improvement and the Safety of Gepotidacin During Treatment of Uncomplicated Urinary Tract Infections (Acute Cystitis)

A Phase 3b, Open-label, Single-arm Study in Adolescent and Adult Female Participants to Evaluate Clinical Symptom Improvement and the Safety of Gepotidacin During Treatment of Uncomplicated Urinary Tract Infections (Acute Cystitis)

Last checked: Nov 20, 2026Latest source record: Feb 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

97

Actual

Start

Oct 2, 2024

Primary completion

Mar 10, 2025

Study completion Mar 10, 2025

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will be conducted to evaluate the clinical symptom improvement and safety of oral gepotidacin for treatment of uncomplicated UTI (acute cystitis) in adolescent and adult female participants.

Conditions

  • Urinary Tract Infections

Interventions

  • GepotidacinDrug

    Gepotidacin will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Clinical Symptom Improvement at 24 Hours (±4 Hours)Time frame: At 24 hours (h) (±4 h)

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Modesto, California

  • GSK Investigational Site

    Pasadena, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    Valencia, California

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Ormond Beach, Florida

  • GSK Investigational Site

    Palm Springs, Florida

  • GSK Investigational Site

    Palm Springs, Florida

  • GSK Investigational Site

    Plant City, Florida

  • GSK Investigational Site

    Sweetwater, Florida

  • GSK Investigational Site

    West Palm Beach, Florida

  • GSK Investigational Site

    West New York, New Jersey

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    Dayton, Ohio

  • GSK Investigational Site

    Forney, Texas

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    Kingwood, Texas

  • GSK Investigational Site

    Mesquite, Texas

  • GSK Investigational Site

    Missouri City, Texas

  • GSK Investigational Site

    Bountiful, Utah

  • GSK Investigational Site

    Morgantown, West Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.